In this article, we will take a look at the 12 Best Slow Growth Stocks to Invest In.
On the night of November 27, during a week cut by Thanksgiving, stock futures saw minimal movement, with the Nasdaq Composite poised to end a seven-month winning run. All things considered, November has been a challenging month for markets. With this week’s advances, the three major averages have reduced their monthly losses, though they are all still on course for a losing month since some high-flying tech stocks have lost momentum due to concerns about high valuations.
However, some investors are hoping that this month’s decline will indicate that the major averages will see a year-end rally as they pick up stocks that have been unfairly hit at more appealing valuations.
That said, the US economy seems to be relatively stable despite growing rumors of a slowdown brought on by tariffs and other challenges. Though job markets have exhibited some downturn, nothing concerning has taken place just yet. According to Arindam Mandal, Head of Global Equities at Marcellus Investment Managers:
“Real wage growth has been positive for a while. Unemployment has drifted higher, but at a slow and controlled pace that can help ease inflation pressures. As long as unemployment stays comfortably below 5%, the economy is not showing the typical signs of a downturn.”
Our Methodology
For this list of slow growth stocks we focused on companies known for stability, predictable cash flows, and long-term durability rather than rapid expansion. These stocks exhibit modest but reliable growth rates, with a 5-year revenue growth rate of less than 10% alongside stable dividend payouts. We also used the number of hedge fund investors as a secondary metric to rank the stocks, as of Q3 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
12. Novartis AG (NYSE:NVS)
5-Year Revenue Growth: 1.13%
Dividend Yield: 3.34%
Number of Hedge Fund Holders: 33
Novartis AG (NYSE:NVS) ranks among the best slow growth stocks to invest in. Following meetings with Novartis AG (NYSE:NVS)’s head of U.S. operations in Boston, New York, and San Francisco, TD Cowen reaffirmed its Hold rating on the company’s shares on November 10 with a price target of $140. The meetings revealed a number of growth drivers that support Novartis’ estimated 6% sales CAGR from 2024 to 2029.
Existing medicines like Cosentyx, Pluvicto, Kisqali, Leqvio, Kesimpta, and Scemblix were noted as significant growth contributors and are anticipated to assist the company in overcoming generic erosion challenges, especially for Entresto.
TD Cowen also emphasized Novartis’ stronger foothold in immunology through Rhapsido and ianalumab, which the firm termed as “substantially de-risked” given recent clinical evaluations and poised to contribute meaningfully to growth before 2030.
Additionally, on November 20, the Swiss drugmaker revised its mid-term sales target for 2025-2030 to reflect a CAGR of 5-6% in constant currencies. Novartis AG (NYSE:NVS) also stated that it aims to return to margins above 40% by 2029, after absorbing 1-2 percentage points of dilution from the anticipated acquisition of Avidity Biosciences.
Novartis AG (NYSE:NVS) is an innovative medicines company that discovers, develops, and manufactures treatments designed to improve and extend lives while tackling serious diseases.
Hedge Fund Resource Center